AR018945A1 - Compuestos beta lactama utilizados como inhibidores de triptasa, las composiciones farmaceuticas que los contienen y los procesos para preparar dichoscompuestos - Google Patents
Compuestos beta lactama utilizados como inhibidores de triptasa, las composiciones farmaceuticas que los contienen y los procesos para preparar dichoscompuestosInfo
- Publication number
- AR018945A1 AR018945A1 ARP990103064A ARP990103064A AR018945A1 AR 018945 A1 AR018945 A1 AR 018945A1 AR P990103064 A ARP990103064 A AR P990103064A AR P990103064 A ARP990103064 A AR P990103064A AR 018945 A1 AR018945 A1 AR 018945A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- cycloalkyl
- heterocycloalkyl
- heteroaryl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen compuestos beta lactamas de las formulas (I), (II), (III), (IV) y (V) y el uso de tales compuestos como inhibidores de varios sistemas deenzima in vivo que incluyen triptasa, trombina, tripsina, Factor Xa, Factor VIIa, y activador depla sminogeno tipo urocinasa. Se revela además el uso de loscompuestos de formula (VI) con triptasa, Factor Xa, e inhibidores del activador de plasminogeno tipo urocinasa, incluye una sal interna del mismo, o una salaceptable farmacéuticamente delmismo, un éster hidrolizable del mismo, o solvato del mismo en donde: R1 es hidrogeno, carboxi, alcoxicarbonilo, A2-arilo,-C(:O)-arilo-SO2-R7, o se selecciona del grupo de formulas (VII), o R1 es alquilo con la condicion de que R2 es alquilo y R3 eshidrog eno; R2 y R3 son amboshidrogeno, o R2 es alquilo con la condicion de que R3 es hidrogeno, o R3 es alquilo con la condicion de que R2 es hidrogeno; X1 se selecciona del grupo (VIII);A1 es grupo (IX);R4 y R5 son seleccionados independientementede H, a lquilo, alquilo substituido, cicloalquilo, cicloalquilo substituido, A2-cicloalquilo,A2-cicloalquilo substituido, arilo, arilo substituido, A2-arilo, A2-arilo substituido, aril-A3-arilo, A2-aril-A3-arilo, heteroarilo,A2-heteroarilo,heterocicloalquil o, A2-heterocicloalquilo, aril-A3-cicloalquilo, A2-aril-A3-cicloalquilo, aril-A3-heteroarilo, aril-A3-heterocicloalquilo, A2-aril-A3-heteroarilo, A2-aril-A3-heterocicloalquilo, cicloalquil-A3-arilo,A2-cicloalquil-A3-arilo, cicloalquil-A3-cicloalquil o, A2-cicloalquil-A3-cicloalquilo,cicloalquil-A3-heteroarilo, A2-cicloalquil-A3-heteroarilo, cicloalquil-A3-heterocicloalquilo y A2-cicloalquil-A3-heterocicloalquilo; R6 es hidrogeno,alquilo,alquilo substituido, cicloalquilo, cicloalquilo substituid o, A2-cicloalquilo, A2-cicloalquilo substituido, arilo, arilo substituido, A2-arilo, A2-arilosubstituido, aril-A3-arilo, A2-aril-A3-arilo, heteroarilo, A2-heteroarilo,heterocicloalquilo, A2-heterocicloalquilo, aril-A3-cicloalquilo, A2-aril-A3-cicloa lquilo, aril-A3-heteroarilo, A2-aril-A3-heteroarilo, aril-A3-heterocicloalquilo, A2-aril-A3-heterocicloalquilo, carboxi, alcoxicarbonilo,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9063698P | 1998-06-25 | 1998-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018945A1 true AR018945A1 (es) | 2001-12-12 |
Family
ID=22223632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103064A AR018945A1 (es) | 1998-06-25 | 1999-06-25 | Compuestos beta lactama utilizados como inhibidores de triptasa, las composiciones farmaceuticas que los contienen y los procesos para preparar dichoscompuestos |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1089973B1 (es) |
| JP (1) | JP2002518478A (es) |
| KR (1) | KR20010053173A (es) |
| CN (1) | CN1202081C (es) |
| AR (1) | AR018945A1 (es) |
| AT (1) | ATE309211T1 (es) |
| AU (1) | AU752320B2 (es) |
| BR (1) | BR9911373A (es) |
| CA (1) | CA2336003A1 (es) |
| DE (1) | DE69928257T2 (es) |
| ES (1) | ES2249017T3 (es) |
| HU (1) | HUP0104308A3 (es) |
| ID (1) | ID27137A (es) |
| IL (1) | IL140414A0 (es) |
| NO (1) | NO20006380L (es) |
| NZ (1) | NZ507627A (es) |
| PE (1) | PE20000729A1 (es) |
| PL (1) | PL345067A1 (es) |
| RU (1) | RU2211832C2 (es) |
| TR (1) | TR200003859T2 (es) |
| TW (1) | TW548270B (es) |
| UY (1) | UY25580A1 (es) |
| WO (1) | WO1999067215A1 (es) |
| ZA (1) | ZA200006028B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063704A1 (ja) | 2003-12-25 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | アゼチジン環化合物およびその医薬 |
| WO2006062110A1 (ja) * | 2004-12-06 | 2006-06-15 | Banyu Pharmaceutical Co., Ltd. | ピペラジン誘導体 |
| US8772297B2 (en) * | 2010-02-17 | 2014-07-08 | Kyoto University | TGF-β signal transduction inhibitor |
| MX2015013374A (es) * | 2013-03-20 | 2016-01-08 | Hoffmann La Roche | Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag). |
| WO2014173855A1 (en) | 2013-04-22 | 2014-10-30 | Reuter Chemische Apparatebau Kg | Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine |
| EP3036219A4 (en) | 2013-06-04 | 2017-08-23 | Temple University Of The Commonwealth System Of Higher Education | Novel beta lactams as modulators of glutamate uptake and methods for use thereof |
| CN106029064B (zh) | 2014-02-07 | 2018-08-14 | 艾克赛特赫拉制药有限责任公司 | 治疗化合物和组合物 |
| JP7397797B2 (ja) | 2018-02-07 | 2023-12-13 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
| EP3778588A4 (en) * | 2018-03-30 | 2021-04-28 | Shanghai Meiyue Biotech Development Co., Ltd. | QUATERNARY LACTAM COMPOUND AND ITS PHARMACEUTICAL USE |
| CN109988098A (zh) * | 2019-05-23 | 2019-07-09 | 常州工程职业技术学院 | 一种(r)-n-叔丁氧羰基-3-羟甲基哌啶的合成方法 |
| CN114040908A (zh) * | 2019-06-25 | 2022-02-11 | 广东东阳光药业有限公司 | 一种凝血因子XIa抑制剂的晶型及其制备方法 |
| AU2020378643A1 (en) | 2019-11-08 | 2022-06-02 | Coave Therapeutics | Modified adeno-associated virus vectors and delivery thereof into the central nervous system |
| IL302444A (en) * | 2020-11-06 | 2023-06-01 | Coave Therapeutics | Lactam muscle adeno-associated virus vectors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037819A (en) * | 1990-06-04 | 1991-08-06 | Bristol-Myers Squibb Company | Azetidin-2-one derivatives as serine protease inhibitors |
| US5250677A (en) * | 1990-06-04 | 1993-10-05 | Bristol-Myers Squibb Company | Azetidin-2-one derivatives as serine protease inhibitors |
| US5175283A (en) * | 1990-06-04 | 1992-12-29 | Bristol-Myers Squibb Company | Azetidin-2-one derivatives as serine protease inhibitors |
| US5110812A (en) * | 1990-06-04 | 1992-05-05 | Bristol-Myers Squibb Co. | Azetidin-2-one derivatives as serine protease inhibitors |
| US5747485A (en) * | 1995-04-13 | 1998-05-05 | Merck & Co., Inc. | Substituted azetidiones as anti-inflammatory and antidegenerative agents |
| CA2266639A1 (en) * | 1996-09-23 | 1998-03-26 | Rajeshwar Singh | 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
-
1999
- 1999-06-18 CN CNB99807845XA patent/CN1202081C/zh not_active Expired - Fee Related
- 1999-06-18 AT AT99930402T patent/ATE309211T1/de not_active IP Right Cessation
- 1999-06-18 KR KR1020007014750A patent/KR20010053173A/ko not_active Application Discontinuation
- 1999-06-18 EP EP99930402A patent/EP1089973B1/en not_active Expired - Lifetime
- 1999-06-18 BR BR9911373-2A patent/BR9911373A/pt not_active IP Right Cessation
- 1999-06-18 JP JP2000555869A patent/JP2002518478A/ja active Pending
- 1999-06-18 DE DE69928257T patent/DE69928257T2/de not_active Expired - Fee Related
- 1999-06-18 CA CA002336003A patent/CA2336003A1/en not_active Abandoned
- 1999-06-18 IL IL14041499A patent/IL140414A0/xx unknown
- 1999-06-18 AU AU46950/99A patent/AU752320B2/en not_active Ceased
- 1999-06-18 ID IDW20002643A patent/ID27137A/id unknown
- 1999-06-18 PL PL99345067A patent/PL345067A1/xx not_active Application Discontinuation
- 1999-06-18 WO PCT/US1999/013811 patent/WO1999067215A1/en active IP Right Grant
- 1999-06-18 TR TR2000/03859T patent/TR200003859T2/xx unknown
- 1999-06-18 RU RU2001102266/04A patent/RU2211832C2/ru not_active IP Right Cessation
- 1999-06-18 NZ NZ507627A patent/NZ507627A/en unknown
- 1999-06-18 HU HU0104308A patent/HUP0104308A3/hu unknown
- 1999-06-18 ES ES99930402T patent/ES2249017T3/es not_active Expired - Lifetime
- 1999-06-21 TW TW088110361A patent/TW548270B/zh not_active IP Right Cessation
- 1999-06-24 UY UY25580A patent/UY25580A1/es not_active Application Discontinuation
- 1999-06-25 AR ARP990103064A patent/AR018945A1/es unknown
- 1999-06-25 PE PE1999000579A patent/PE20000729A1/es not_active Application Discontinuation
-
2000
- 2000-10-25 ZA ZA200006028A patent/ZA200006028B/xx unknown
- 2000-12-14 NO NO20006380A patent/NO20006380L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20000729A1 (es) | 2000-10-28 |
| ATE309211T1 (de) | 2005-11-15 |
| BR9911373A (pt) | 2001-09-18 |
| TR200003859T2 (tr) | 2001-07-23 |
| EP1089973A4 (en) | 2001-12-12 |
| AU4695099A (en) | 2000-01-10 |
| DE69928257T2 (de) | 2006-08-03 |
| EP1089973B1 (en) | 2005-11-09 |
| KR20010053173A (ko) | 2001-06-25 |
| EP1089973A1 (en) | 2001-04-11 |
| ZA200006028B (en) | 2002-09-25 |
| HUP0104308A2 (hu) | 2002-04-29 |
| NO20006380D0 (no) | 2000-12-14 |
| NZ507627A (en) | 2003-12-19 |
| UY25580A1 (es) | 2001-08-27 |
| ID27137A (id) | 2001-03-01 |
| NO20006380L (no) | 2000-12-14 |
| WO1999067215A1 (en) | 1999-12-29 |
| DE69928257D1 (de) | 2005-12-15 |
| PL345067A1 (en) | 2001-12-03 |
| ES2249017T3 (es) | 2006-03-16 |
| JP2002518478A (ja) | 2002-06-25 |
| CA2336003A1 (en) | 1999-12-29 |
| CN1307560A (zh) | 2001-08-08 |
| CN1202081C (zh) | 2005-05-18 |
| IL140414A0 (en) | 2002-02-10 |
| HUP0104308A3 (en) | 2002-06-28 |
| AU752320B2 (en) | 2002-09-12 |
| RU2211832C2 (ru) | 2003-09-10 |
| TW548270B (en) | 2003-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018945A1 (es) | Compuestos beta lactama utilizados como inhibidores de triptasa, las composiciones farmaceuticas que los contienen y los procesos para preparar dichoscompuestos | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| BRPI0114704B8 (pt) | composto de imidazol fundido a arila ou heteroarila, suas composições farmacêuticas, bem como seu uso | |
| AR011093A1 (es) | Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso. | |
| ES2102668T3 (es) | Composiciones detergentes liquidas que contienen proteasa y ciertos acidos y esteres beta-aminoalquilboronicos. | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| AR013094A1 (es) | Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| MXPA04006709A (es) | Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen. | |
| AR056876A1 (es) | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares | |
| AR006391A1 (es) | Compuesto de 6-fenilpiridil-2-amina y composiciones farmaceuticas del mismo | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
| FI810250L (fi) | Foerfarande foer framstaellning av nya terapeutiskt aktiva heterocykliska foereningar | |
| AR009070A1 (es) | Compuestos derivados de amidinas heterociclicas de cinco miembros, su uso y compuestos intermediarios utiles para la produccion de los mismos. | |
| CO4920225A1 (es) | 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas | |
| PE20080355A1 (es) | Compuestos peptidicos como inhibidores de proteasa de serina del virus de hepatitis c | |
| PE20090548A1 (es) | Compuestos aza-biciclohexano como inhibidores de trombina | |
| PE20050231A1 (es) | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| EA200100882A1 (ru) | Гетероарильные производные амидина, метиламидина и гуанидина (варианты), способ их получения, фармацевтическая композиция (варианты), способ ингибирования протеазы (варианты) и способ лечения различных заболеваний (варианты) | |
| HUP9801072A2 (hu) | Szubsztituált 6-és 7-amino-tetrahidro-izokinolin-karbonsav-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| AR041854A1 (es) | Derivados de [6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-sulfonilamino]-propionamida utiles como antiinflamatorios | |
| PE20050336A1 (es) | Compuestos triciclicos como inhibidores de la proteina farnesil transferasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |